hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06295796, orgStudyIdInfo id: 8527-008, secondaryIdInfos id: MK-8527-008, type: OTHER, domain: Merck, briefTitle: A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-17, primaryCompletionDateStruct date: 2025-04-14, completionDateStruct date: 2025-04-14, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Merck Sharp & Dohme LLC, class: INDUSTRY, descriptionModule briefSummary: The goal of this study is to evaluate the effect of moderate and severe renal impairment (RI) on the pharmacokinetics (PK), safety, and tolerability of MK-8527. There will be no hypothesis testing in the study., conditionsModule conditions: Renal Impairment, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: MK-8527, outcomesModule primaryOutcomes measure: Area under the concentration versus time curve from time 0 to last quantifiable sample (AUC0-last) of MK-8527 in plasma, primaryOutcomes measure: Area under the concentration versus time curve from time 0 to infinity (AUC0-inf) of MK-8527 in plasma, primaryOutcomes measure: Maximum concentration (Cmax) of MK-8527 in plasma, primaryOutcomes measure: Time to Maximum concentration (Tmax) of MK-8527 in plasma, primaryOutcomes measure: Apparent terminal half-life (t1/2) of MK-8527 in plasma, primaryOutcomes measure: Apparent Clearance (CL/F) of MK-8527 in plasma, primaryOutcomes measure: Apparent volume of distribution during terminal phase (Vz/F) of MK-8527 in plasma, secondaryOutcomes measure: Number of participants who experience one or more adverse events (AEs), secondaryOutcomes measure: Number of participants who discontinue study due to an AE, secondaryOutcomes measure: AUC0-last of MK-8527-triphosphate (TP) in peripheral blood mononuclear cells (PBMCs), secondaryOutcomes measure: AUC0-inf of MK-8527-TP in PBMCs, secondaryOutcomes measure: Cmax of MK-8527-TP in PBMCs, secondaryOutcomes measure: Concentration at 168 hours (C168) of MK-8527-TP in PBMCs, secondaryOutcomes measure: Concentration at 672 hours (C672) of MK-8527-TP in PBMCs, secondaryOutcomes measure: Tmax of MK-8527-TP in PBMCs, secondaryOutcomes measure: t1/2 of MK-8527-TP in PBMCs, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06295783, orgStudyIdInfo id: 2023-1059, secondaryIdInfos id: NCI-2024-01955, type: OTHER, domain: NCI-CTRP Clinical Registry, briefTitle: Prospective Evaluation of the Relation Between Different Questionnaires Measuring Radiation-induced Side-effect, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08-31, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2027-02-01, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: M.D. Anderson Cancer Center, class: OTHER, descriptionModule briefSummary: To learn more about how you would rate the intensity or severity of your symptoms during or after radiation therapy using questionnaires with different rating scales., conditionsModule conditions: Radiation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: MDASI-HN, interventions name: EORTC QLQ-C30, interventions name: EORTC HN35, outcomesModule primaryOutcomes measure: Safety and adverse events (AEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MD Anderson Cancer Center, city: Houston, state: Texas, zip: 77030, country: United States, contacts name: Amy Moreno, MD, role: CONTACT, phone: 713-745-4590, email: akmoreno@mdanderson.org, contacts name: Amy Moreno, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 29.76328, lon: -95.36327, hasResults: False
protocolSection identificationModule nctId: NCT06295770, orgStudyIdInfo id: 23-006712, briefTitle: Obinutuzumab in Treatment of Fibrillary Glomerulonephritis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-04-01, completionDateStruct date: 2027-04-01, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The purpose of this research is to learn if Obinutuzumab is effective and safe in treating patients with fibrillary glomerulonephritis (FGN)., conditionsModule conditions: Fibrillary Glomerulonephritis, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Obinutuzumab, outcomesModule primaryOutcomes measure: Change in proteinuria from baseline to 12 months post treatment with Obinutuzumab, secondaryOutcomes measure: Change in proteinuria from baseline to 6 months post treatment with Obinutuzumab, secondaryOutcomes measure: Rate of complete or partial remission, secondaryOutcomes measure: Improvement in serum albumin, secondaryOutcomes measure: Stabilization of kidney function, secondaryOutcomes measure: Serious Adverse Events (SAEs), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Angela Reinke, role: CONTACT, phone: 507-266-1047, email: Reinke.Angela@mayo.edu, contacts name: Nicholas Geroux, role: CONTACT, phone: 507-266-0956, email: Geroux.Nicholas@mayo.edu, contacts name: Ladan Zand, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06295757, orgStudyIdInfo id: 2023LS102, briefTitle: Effects of Relighting on Smoke Toxicant Deliveries and Subjective Smoking Measures, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-01-01, completionDateStruct date: 2027-01-01, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Masonic Cancer Center, University of Minnesota, class: OTHER, collaborators name: National Institutes of Health (NIH), descriptionModule briefSummary: Characterize effects of relighting on smoke toxicant deliveries and subjective smoking measures. This will be a within-subject comparison in a single experimental group of 30 smokers who report engaging in relighting behaviors. We will assess smoking intensity for relit and non-relit (i.e., smoked continuously without relighting) cigarettes in the natural environment and will conduct in-clinic measurements of smoking topography and subjective responses for relit and non-relit cigarettes. Information on relighting patterns and smoking topography collected from each participant will be used to compare machine-measured smoke yields of key harmful constituents when their usual cigarettes are smoked with and without relighting. Hypothesis: Relit cigarettes will produce higher levels of toxicants than non-relit cigarettes., conditionsModule conditions: Tobacco Use, conditions: Cigarette Smoking, conditions: Nicotine Dependence, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Cigarettes, outcomesModule primaryOutcomes measure: Average Nicotine Level, secondaryOutcomes measure: Average Puff Volume, eligibilityModule sex: ALL, minimumAge: 21 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06295744, orgStudyIdInfo id: 2023-1724, secondaryIdInfos id: Protocol Version 2/5/2024, type: OTHER, domain: UW Madison, secondaryIdInfos id: A533300, type: OTHER, domain: UW Madison, secondaryIdInfos id: UW23114, type: REGISTRY, domain: UWCCC OnCore ID, briefTitle: Outcomes and Cosmesis With Whole Breast Irradiation and Boost, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-17, primaryCompletionDateStruct date: 2029-02, completionDateStruct date: 2032-02, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: University of Wisconsin, Madison, class: OTHER, descriptionModule briefSummary: This study is being done to evaluate cosmetic, patient-reported outcome measures (PROMs), and toxicities for women undergoing ultra-short whole breast irradiation (WBI) therapy with simultaneous integrated boost (SIB). 50 participants will be on study for up to 60 months., conditionsModule conditions: Early-stage Breast Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Radiation Therapy, outcomesModule primaryOutcomes measure: Harvard Breast Cosmesis Scale Score, secondaryOutcomes measure: Change in BREAST-Q Score, secondaryOutcomes measure: Incidence of Acute Toxicities, secondaryOutcomes measure: Incidence of Late Toxicities, secondaryOutcomes measure: Ipsilateral Breast Tumor Recurrence-Free Survival, secondaryOutcomes measure: Overall Survival (OS), eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UW Carbone Cancer Center, status: RECRUITING, city: Madison, state: Wisconsin, zip: 53792, country: United States, geoPoint lat: 43.07305, lon: -89.40123, hasResults: False
protocolSection identificationModule nctId: NCT06295731, orgStudyIdInfo id: INBRX106-01-201, secondaryIdInfos id: EU CT, type: OTHER, domain: 2024-511323-34, briefTitle: INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2029-05, completionDateStruct date: 2029-05, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Inhibrx, Inc., class: INDUSTRY, descriptionModule briefSummary: This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20., conditionsModule conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Phase 2: open label; Phase 3: double-blind, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 410, type: ESTIMATED, armsInterventionsModule interventions name: INBRX-106, interventions name: Pembrolizumab, outcomesModule primaryOutcomes measure: Phase 2: Objective Response Rate (ORR), primaryOutcomes measure: Phase 3: Progression-Free Survival (PFS), primaryOutcomes measure: Phase 3: Overall Survival (OS), secondaryOutcomes measure: Phase 3: Objective Response Rate (ORR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Clinical Benefit Rate (CBR), secondaryOutcomes measure: Phase 3: Time to Chemotherapy (TTCtx), secondaryOutcomes measure: Time to Confirmed Deterioration (TTCD) in Pain Presence and Interference, secondaryOutcomes measure: TTCD in physical functioning (PF), secondaryOutcomes measure: TTCD in role functioning (RF), secondaryOutcomes measure: TTCD in Global Health Status/quality of life (GHS/QoL), secondaryOutcomes measure: Incidence and severity of Adverse Events (AEs), secondaryOutcomes measure: Number of patients who experienced abnormalities in vital signs and clinical laboratory parameters, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06295718, orgStudyIdInfo id: 2023/51, briefTitle: Tele-assessment of Functional Performance and Quality of Life in Patients With Duchenne Muscular Dystrophy: Validity and Reliability Study, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-07-01, primaryCompletionDateStruct date: 2024-03-02, completionDateStruct date: 2024-05-10, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Sahra Şirvan, class: OTHER, descriptionModule briefSummary: Thanks to tele-assessment methods, it may be possible to evaluate DMD patients without traveling to clinical centers. In recent years, the applicability of remote assessment methods in DMD patients, as in many populations, is being investigated. However, studies have generally focused on a single evaluation parameter such as physical function, a special evaluation method or a special evaluation tool. The aim of this study is to investigate whether remote assessment of functional performance and quality of life in DMD patients is valid and reliable. If a valid and reliable tele-evaluation method that includes functional performance and quality of life parameters is found to be valid and reliable, the travel burden on patients and caregivers can be eased, patients\&#39; stress and anxiety related to travel can be reduced, caregivers can save time and energy and provide patients with the best possible treatment., conditionsModule conditions: Duchenne Muscular Dystrophy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Timed Performance Tests, primaryOutcomes measure: Brooke Upper Extremity Functional Classification (BUEFS), primaryOutcomes measure: Vignos Lower Extremity Functional Classification (VAEFS), primaryOutcomes measure: PedsQL-3.0 Neuromuscular Module by PedsQL Multidimensional Fatigue Scale, eligibilityModule sex: MALE, minimumAge: 5 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: İstanbul University - Cerrahpaşa, city: Istanbul, zip: 34758, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06295705, orgStudyIdInfo id: 5230588, briefTitle: Exploring the Effectiveness of Dance as an Intervention to Promote Social-Emotional Health in Children With Autism Spectrum Disorder (ASD), acronym: ASD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-02, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-04, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Loma Linda University, class: OTHER, descriptionModule briefSummary: This study will explore the effectiveness of dance as an intervention to promote social-emotional health within children with ASD., conditionsModule conditions: Autism Spectrum Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 12, type: ESTIMATED, armsInterventionsModule interventions name: Hip-Hop Dance, outcomesModule primaryOutcomes measure: Child Description of Impact on Social-Emotional Health, secondaryOutcomes measure: Parent Perspective of Impact on Social-Emotional Health, secondaryOutcomes measure: Change in Social-Emotional Behavior, eligibilityModule sex: ALL, minimumAge: 7 Years, maximumAge: 11 Years, stdAges: CHILD, contactsLocationsModule locations facility: Loma Linda University Health, status: RECRUITING, city: Loma Linda, state: California, zip: 92350, country: United States, contacts name: Julie Kugel, OTD, role: CONTACT, phone: 909-558-4628, phoneExt: 47473, email: jkugel@llu.edu, geoPoint lat: 34.04835, lon: -117.26115, hasResults: False
protocolSection identificationModule nctId: NCT06295666, orgStudyIdInfo id: 26.12.2018/901, briefTitle: Gingival Crevicular Fluid (GCF) Bactericidal Permeability Protein (BPI) and Interleukin (IL)-1 Beta, statusModule overallStatus: COMPLETED, startDateStruct date: 2019-02-19, primaryCompletionDateStruct date: 2019-11-25, completionDateStruct date: 2020-01-20, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Akdeniz University, class: OTHER, descriptionModule briefSummary: Objective: The aim of this study is to determine the amounts of BPI (Bactericidal permeability protein) and interleukin-1beta (IL-1β) in gingival fluid samples obtained from individuals with periodontally healthy and periodontal disease, to compare these amounts between study groups, and to evaluate their relationship with clinical parameters. In cases where clinical parameters increase, IL-1β amounts also increase significantly. The amount of IL-1β in individuals with periodontal disease is significantly higher compared to healthy individuals. There is positive correlation between BPI and clinical parameters. The amount of BPI in individuals with periodontal disease is significantly higher than in healthy individuals. More studies are needed to better understand the importance and therapeutic effect of BPI in periodontitis, conditionsModule conditions: Periodontitis, conditions: Gingival Crevicular Fluid, conditions: Interleukin 1-beta, conditions: Bactericidal Permeability Protein, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ACTUAL, armsInterventionsModule, outcomesModule primaryOutcomes measure: Gingival Crevicular Fluid Bactericidal Permeability Increasing Protein levels in periodonitis, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Akdeniz Üniversitesi Diş Hekimliği Fakültesi, city: Antalya, country: Turkey, geoPoint lat: 36.90812, lon: 30.69556, hasResults: False
protocolSection identificationModule nctId: NCT06295653, orgStudyIdInfo id: 7-23, briefTitle: Subepithelial Connective Tissue Graft Versus Amniotic Chorion Membrane for Peri-implant Mucosal Thickness Enhancement, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: The objective of this study will be to assess the efficacy of the peri-implant mucosal thickness enhancement following either subepithelial connective tissue grafts or Amnion Chorion Membrane placed simultaneously with dental implant placement., conditionsModule conditions: Dental Implant, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 26, type: ESTIMATED, armsInterventionsModule interventions name: implant placement and soft tissue augmentation with Autogenous Subepithelial Connective Tissue Graft or Amniotic Chorion Membrane, outcomesModule primaryOutcomes measure: measure changes in periimplant mucosal thickness, secondaryOutcomes measure: mid-buccal keratinized mucosal width, eligibilityModule sex: ALL, minimumAge: 30 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule locations facility: Faculity of Dentistry Tanta University, city: Tanta, state: Elgarbia, zip: 6620012, country: Egypt, contacts name: Faten a Seddiq, Faculty Dean, role: CONTACT, phone: 3335631, phoneExt: +20, email: dean_dent@unv.tanta.edu.eg, contacts name: ahmed a abdelsayed, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.78847, lon: 31.00192, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2024-03-03, uploadDate: 2024-03-03T10:57, filename: Prot_SAP_000.pdf, size: 472866, hasResults: False
protocolSection identificationModule nctId: NCT06295640, orgStudyIdInfo id: 300/2022, briefTitle: Relative Contribution of Brain Insulin Action for Postprandial Metabolism, acronym: BrainInsPPM, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-03-06, lastUpdatePostDateStruct date: 2024-03-27, sponsorCollaboratorsModule leadSponsor name: University of Ulm, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to clarify (i) the contribution of brain insulin action on regulation of systemic metabolism, (ii) sex-specific differences in the central regulation and (iii) the influence of the menstrual cycle in women.Therefore, participants will undergo oral glucose tolerance tests combined with a double tracer dilution technique. This approach will be compared between days with insulin delivery to the brain as nasal spray and days with placebo spray., conditionsModule conditions: Glucose Metabolism Disorders, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: Randomized, controlled, cross-over design for men. Randomized, controlled, 2x2 factorial cross-over design for women taking the menstrual cycle phase into account., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Oral glucose tolerance test with double-tracer dilution and intranasal insulin spray, interventions name: Oral glucose tolerance test with double-tracer dilution and intranasal placebo spray, outcomesModule primaryOutcomes measure: Endogenous glucose production, primaryOutcomes measure: Rate of glucose disappearance, secondaryOutcomes measure: Proglucagon cleavage products, secondaryOutcomes measure: Glucose tolerance, secondaryOutcomes measure: Whole-body insulin sensitivity, secondaryOutcomes measure: Insulin secretion, secondaryOutcomes measure: Post-absorptive energy expenditure, secondaryOutcomes measure: Sex differences, secondaryOutcomes measure: Menstrual cycle effects, secondaryOutcomes measure: Autonomic nervous system activity, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: Universityhospital Ulm, status: RECRUITING, city: Ulm, zip: 89081, country: Germany, contacts name: Julia Hummel, Phd, role: CONTACT, phone: +4973150044744, email: julia.hummel@uniklinik-ulm.de, contacts name: Rebecca Spies, MD, role: CONTACT, email: rebecca.spies@uniklinik-ulm.de, geoPoint lat: 48.39841, lon: 9.99155, hasResults: False